RJA
DNA icon

Raymond James & Associates’s Ginkgo Bioworks DNA Stock Holding History

Raymond James & Associates’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,538
Closed -$20.6K – 4023
2024
Q2 		$20.6K Sell
1,538
-2,921
-66% -$87.2K ﹤0.01% 3889
2024
Q1 		$207K Sell
4,459
-33
-0.7% -$1.71K ﹤0.01% 3600
2023
Q4 		$304K Sell
4,492
-348
-7% -$21.3K ﹤0.01% 3272
2023
Q3 		$350K Buy
4,840
+212
+5% +$16.9K ﹤0.01% 3098
2023
Q2 		$344K Buy
4,628
+260
+6% +$15.4K ﹤0.01% 3155
2023
Q1 		$232K Buy
4,368
+201
+5% +$12.7K ﹤0.01% 3409
2022
Q4 		$282K Sell
4,167
-312
-7% -$28.7K ﹤0.01% 3256
2022
Q3 		$559K Buy
4,479
+1,466
+49% +$175K ﹤0.01% 2786
2022
Q2 		$287K Buy
3,013
+790
+36% +$96.4K ﹤0.01% 3263
2022
Q1 		$358K Buy
2,223
+1,667
+300% +$324K ﹤0.01% 3292
2021
Q4 		$185K Sell
556
-657
-54% -$312K ﹤0.01% 3722
2021
Q3 		$562K Buy
+1,213
New +$590K ﹤0.01% 2981

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James & Associates's DNA Position: Q3 2024 in Review

Raymond James & Associates sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 1,538 shares — an estimated $20.6K sold.

Raymond James & Associates first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $562K in Q3 2021. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Raymond James & Associates reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 1,538 Ginkgo Bioworks shares in Q3 2024, an estimated $20.6K.
  • Raymond James & Associates first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Raymond James & Associates's Ginkgo Bioworks position peaked at $562K in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.